MOMA Therapeutics
Biopharmaceutical company pioneering the discovery and development of precision medicines targeting molecular machines—proteins that drive cellular processes and underlie human disease.
Website
https://www.momatx.comLocation
Cambridge, Massachusetts, USA
Founded
2019
Investors
1
Categories
therapeutics, biotech, precision-medicine, molecular-machines, drug-discovery
Notes
MOMA Therapeutics is a biopharmaceutical company focused on developing precision medicines that target molecular machines—the protein complexes that power essential cellular processes. The company's approach enables it to drug previously undruggable targets by understanding and exploiting the unique biology of these dynamic molecular machines.
MOMA's platform integrates structural biology, biochemistry, and medicinal chemistry to identify and develop novel therapeutics against molecular machines implicated in cancer and other serious diseases.
Team
- Ramy Farid, Ph.D. - Co-Founder
- Silvia Bheddah - Chief Executive Officer
- LinkedIn: linkedin.com/in/silviabheddah
Additional Research Findings
- Founded in 2019
- Headquarters in Cambridge, Massachusetts
- Backed by Alexandria Venture Investments and other life sciences investors
- Focus on molecular machines as therapeutic targets
- Platform enables targeting undruggable proteins
- Oncology-focused pipeline
- Structural biology-driven drug discovery
- Part of Cambridge/Boston biotech hub
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Alexandria Venture Investments | Pasadena, USA | cvc | seedseries-a+3 | 6 |